Frank Loganzo
Pfizer (United States)(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Microtubule and mitosis dynamics, Cancer Treatment and Pharmacology, Cell Adhesion Molecules Research
Most-Cited Works
- Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.(1995)
- → Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments(2015)259 cited
- → Mechanisms of Resistance to Antibody–Drug Conjugates(2016)205 cited
- → Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)(2017)199 cited
- → Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy(2014)185 cited
- → Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?(2015)179 cited
- → Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules(2006)146 cited
- HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.(2003)
- → Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications(2014)131 cited
- → Potentiation of Apoptosis by Treatment With the Protein Kinase C-Specific Inhibitor Safingol in Mitomycin C-Treated Gastric Cancer Cells(1995)115 cited